An AtriCure Director Sold $905,000 in Stock. Here's How to Read It
Prange's open-market disposition reduced her direct holdings by 14%, though she retains over 22,800 shares in the $2.0 billion medical device company.
Overview
Karen Prange, a director of the company, sold 23,325 shares of common stock in AtriCure, Inc. (NASDAQ:ATRC) on August 5, according to an SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($38.80); post-transaction value based on August 5 market close ($39.34).
Details
AtriCure is a focused medical device company with a $2.0 billion market capitalization and $569.6 million in TTM revenue, positioning itself as a specialized provider of cardiac surgical solutions. The company maintains a differentiated product portfolio centered on radiofrequency ablation technology, which provides competitive advantages in the treatment of cardiac arrhythmias and related conditions. With a global distribution network spanning multiple continents, AtriCure has established itself as a significant player in the cardiac surgery device market.
Source
Originally published at www.fool.com.